|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Under hypoxia, dexamethasone treatment inhibited HIF-1α protein level and its downstream gene, VEGF mRNA level in the colon cancer cell lines, HCT116 and HT29.
|
26379394 |
2015 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
|
25224594 |
2015 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
After stratifying by tumor molecular subtype, SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.
|
23794399 |
2014 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Of the gene-environment combined effects, the interaction of VEGF 1451C > T and MetS contributed to increased rectal cancer risk (AOR = 3.15; 95% CI = 1.74 - 5.70; p < .001) whereas the combination of VEGF 1725G > A and MetS was involved with elevated colon cancer risk (AOR = 2.68; 95% CI = 1.30 - 1.55; p =0.008).
|
25423914 |
2014 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer.
|
24555920 |
2014 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
GDNF increases cell motility in human colon cancer through VEGF-VEGFR1 interaction.
|
24165321 |
2014 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, a major implication of our studies is that restoration of miR-192 expression or antagonism of its target genes (Bcl-2, Zeb2 or VEGFA) may have considerable therapeutic potential for anti-metastatic therapy in patients with colon cancer.
|
24213572 |
2014 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.
|
24780003 |
2014 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IHC studies performed on human colon adenocarcinoma specimens showed that TGF-beta signaling is inversely correlated with VEGFA expression, indicating that TGF-beta-mediated suppression of VEGFA expression exists in colon cancer patients.
|
23536895 |
2013 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Negative experience of dual EGFR and VEGF targeting in colon cancer cannot be overlooked.
|
23518595 |
2013 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
While the VEGF levels were increased in the colon tissues of Il-17f(-/-) mice with colon cancer.
|
22509371 |
2012 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
AST decreased the protein level of VEGF and bFGF in HCT 116 colon cancer cells in a time- and dose-dependent manner.
|
22992293 |
2012 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
RGD |
Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1α and VEGF.
|
21268133 |
2011 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further studies are needed to understand the mechanism of VEGF gene polymorphisms in the development and progression of colon cancer.
|
21091242 |
2011 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The secretion of vascular endothelial growth factor (VEGF) was inhibited by single PTX treatment of colon cancer and in continuous treatment of glioblastoma cell lines.
|
21775090 |
2011 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Another monoclonal antibody useful in the treatment of colon cancer is bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF); however, in some cases bevacizumab may cause deep vein thrombosis (DVP).
|
21468552 |
2011 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In our study we evaluated by qRT-PCR the level of expression of 3 growth factors involved in angiogenesis: platelet derived growth factor-B (PDGFb), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) in patients with different stages of colon cancer.
|
21766497 |
2011 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These findings demonstrate that TTP acts as a negative regulator of VEGF gene expression in colon cancer cells, suggesting that it can be used as novel therapeutic agent to treat colon cancer.
|
19697322 |
2010 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our previous studies demonstrated that mutant KRAS alleles can interact with hypoxia to induce vascular endothelial growth factor (VEGF) in colon cancer.
|
20532039 |
2010 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Whereas the inhibition of vascular endothelial growth factor (VEGF) has shown promising results in sporadic colon cancer, the role of VEGF signaling in colitis-associated cancer (CAC) has not been addressed.
|
21098094 |
2010 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neuropilin-1 (NRP-1) has been shown to promote tumour cell migration and survival in colon cancer in response to VEGF binding.
|
20950431 |
2010 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here we investigated the molecular mechanism by which leptin and VEGF expression are regulated in colon cancer by epidermal growth factor (EGF).
|
19492417 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
CTD_human |
Polymorphisms in IL1B, IL1RN, and VEGFA as well as IL1B/IL1RN haplotype analysis may serve as molecular markers for tumor recurrence in stage II colon cancer, indicating that the analysis of angiogenesis-related gene polymorphisms may help to identify patient subgroups at high risk for tumor recurrence.
|
18987561 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although further investigation to clarify the mechanisms explaining the role of Del1 in tumor growth, and the interaction between VEGF and Del1, is required, the results indicate that downregulation of Del1 presents a potent therapeutic strategy to combat colon cancer.
|
19292890 |
2009 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts.
|
18544566 |
2008 |